Gene

Glioblastoma

Poliomyelitis

Adverse effect

Biology

Surgery

Virology

Cancer research

Biochemistry

Phases of clinical research

Environmental health

Immunology

Glioma

Toxicity

Bevacizumab

Population

Internal medicine

Poliovirus

Chemotherapy

Rhinovirus

Oncology

Medicine

Gastroenterology

Virus

Recombinant DNA

New England Journal of Medicine

The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating convection-enhanced, intratumoral delivery of the recombinant nonpathogenic polio–rhinovirus chimera (PVSRIPO). PVSRIPO recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.

Recurrent Glioblastoma Treated with Recombinant Poliovirus